237 related articles for article (PubMed ID: 31019567)
1. First-line afatinib for the treatment of
Park K; Wan-Teck Lim D; Okamoto I; Yang JC
Ther Adv Med Oncol; 2019; 11():1758835919836374. PubMed ID: 31019567
[TBL] [Abstract][Full Text] [Related]
2. Afatinib as First-Line Treatment in Asian Patients with EGFR Mutation-Positive NSCLC: A Narrative Review of Real-World Evidence.
Lu S; Shih JY; Jang TW; Liam CK; Yu Y
Adv Ther; 2021 May; 38(5):2038-2053. PubMed ID: 33730350
[TBL] [Abstract][Full Text] [Related]
3. Afatinib for the treatment of
Harvey RD; Adams VR; Beardslee T; Medina P
J Oncol Pharm Pract; 2020 Sep; 26(6):1461-1474. PubMed ID: 32567494
[TBL] [Abstract][Full Text] [Related]
4. Afatinib versus gefitinib as first-line treatment of patients with EGFR mutation-positive non-small-cell lung cancer (LUX-Lung 7): a phase 2B, open-label, randomised controlled trial.
Park K; Tan EH; O'Byrne K; Zhang L; Boyer M; Mok T; Hirsh V; Yang JC; Lee KH; Lu S; Shi Y; Kim SW; Laskin J; Kim DW; Arvis CD; Kölbeck K; Laurie SA; Tsai CM; Shahidi M; Kim M; Massey D; Zazulina V; Paz-Ares L
Lancet Oncol; 2016 May; 17(5):577-89. PubMed ID: 27083334
[TBL] [Abstract][Full Text] [Related]
5. First-Line Afatinib versus Chemotherapy in Patients with Non-Small Cell Lung Cancer and Common Epidermal Growth Factor Receptor Gene Mutations and Brain Metastases.
Schuler M; Wu YL; Hirsh V; O'Byrne K; Yamamoto N; Mok T; Popat S; Sequist LV; Massey D; Zazulina V; Yang JC
J Thorac Oncol; 2016 Mar; 11(3):380-90. PubMed ID: 26823294
[TBL] [Abstract][Full Text] [Related]
6. Afatinib versus gemcitabine/cisplatin for first-line treatment of Chinese patients with advanced non-small-cell lung cancer harboring
Wu YL; Xu CR; Hu CP; Feng J; Lu S; Huang Y; Li W; Hou M; Shi JH; Märten A; Fan J; Peil B; Zhou C
Onco Targets Ther; 2018; 11():8575-8587. PubMed ID: 30584317
[TBL] [Abstract][Full Text] [Related]
7. First-line treatment of advanced epidermal growth factor receptor (EGFR) mutation positive non-squamous non-small cell lung cancer.
Greenhalgh J; Boland A; Bates V; Vecchio F; Dundar Y; Chaplin M; Green JA
Cochrane Database Syst Rev; 2021 Mar; 3(3):CD010383. PubMed ID: 33734432
[TBL] [Abstract][Full Text] [Related]
8. Second-generation EGFR and ErbB tyrosine kinase inhibitors as first-line treatments for non-small cell lung cancer.
Wang S; Li J
Onco Targets Ther; 2019; 12():6535-6548. PubMed ID: 31496745
[TBL] [Abstract][Full Text] [Related]
9. Afatinib as first-line treatment in patients with
Brückl WM; Reck M; Griesinger F; Schäfer H; Kortsik C; Gaska T; Rawluk J; Krüger S; Kokowski K; Budweiser S; Ficker JH; Hoffmann C; Schüler A; Laack E
Ther Adv Med Oncol; 2021; 13():17588359211012361. PubMed ID: 33995597
[TBL] [Abstract][Full Text] [Related]
10. Afatinib in EGFR TKI-naïve patients with locally advanced or metastatic EGFR mutation-positive non-small cell lung cancer: Interim analysis of a Phase 3b study.
de Marinis F; Laktionov KK; Poltoratskiy A; Egorova I; Hochmair M; Passaro A; Migliorino MR; Metro G; Gottfried M; Tsoi D; Ostoros G; Rizzato S; Mukhametshina GZ; Schumacher M; Novello S; Dziadziuszko R; Tang W; Clementi L; Cseh A; Kowalski D
Lung Cancer; 2021 Feb; 152():127-134. PubMed ID: 33387727
[TBL] [Abstract][Full Text] [Related]
11. First-line treatment of advanced epidermal growth factor receptor (EGFR) mutation positive non-squamous non-small cell lung cancer.
Greenhalgh J; Dwan K; Boland A; Bates V; Vecchio F; Dundar Y; Jain P; Green JA
Cochrane Database Syst Rev; 2016 May; (5):CD010383. PubMed ID: 27223332
[TBL] [Abstract][Full Text] [Related]
12. Experience with afatinib in patients with non-small cell lung cancer progressing after clinical benefit from gefitinib and erlotinib.
Schuler M; Fischer JR; Grohé C; Gütz S; Thomas M; Kimmich M; Schneider CP; Laack E; Märten A;
Oncologist; 2014 Oct; 19(10):1100-9. PubMed ID: 25232040
[TBL] [Abstract][Full Text] [Related]
13. Afatinib as First-line Treatment of Older Patients With EGFR Mutation-Positive Non-Small-Cell Lung Cancer: Subgroup Analyses of the LUX-Lung 3, LUX-Lung 6, and LUX-Lung 7 Trials.
Wu YL; Sequist LV; Tan EH; Geater SL; Orlov S; Zhang L; Lee KH; Tsai CM; Kato T; Barrios CH; Schuler M; Hirsh V; Yamamoto N; O'Byrne K; Boyer M; Mok T; Peil B; Märten A; Chih-Hsin Yang J; Paz-Ares L; Park K
Clin Lung Cancer; 2018 Jul; 19(4):e465-e479. PubMed ID: 29653820
[TBL] [Abstract][Full Text] [Related]
14. Advanced non-small cell lung cancer (NSCLC) with activating EGFR mutations: first-line treatment with afatinib and other EGFR TKIs.
Brückl W; Tufman A; Huber RM
Expert Rev Anticancer Ther; 2017 Feb; 17(2):143-155. PubMed ID: 27898252
[TBL] [Abstract][Full Text] [Related]
15. Epidermal growth factor receptor tyrosine kinase inhibitors for non-small cell lung cancer harboring uncommon EGFR mutations: Real-world data from Taiwan.
Chang JW; Huang CY; Fang YF; Chang CF; Yang CT; Kuo CS; Hsu PC; Wu CE
Thorac Cancer; 2023 Jan; 14(1):12-23. PubMed ID: 36424878
[TBL] [Abstract][Full Text] [Related]
16. Afatinib: A Review in Advanced Non-Small Cell Lung Cancer.
Keating GM
Target Oncol; 2016 Dec; 11(6):825-835. PubMed ID: 27873136
[TBL] [Abstract][Full Text] [Related]
17. Afatinib: a review of its use in the treatment of advanced non-small cell lung cancer.
Keating GM
Drugs; 2014 Feb; 74(2):207-21. PubMed ID: 24435321
[TBL] [Abstract][Full Text] [Related]
18. Afatinib versus gefitinib in patients with EGFR mutation-positive advanced non-small-cell lung cancer: overall survival data from the phase IIb LUX-Lung 7 trial.
Paz-Ares L; Tan EH; O'Byrne K; Zhang L; Hirsh V; Boyer M; Yang JC; Mok T; Lee KH; Lu S; Shi Y; Lee DH; Laskin J; Kim DW; Laurie SA; Kölbeck K; Fan J; Dodd N; Märten A; Park K
Ann Oncol; 2017 Feb; 28(2):270-277. PubMed ID: 28426106
[TBL] [Abstract][Full Text] [Related]
19. Afatinib versus cisplatin plus gemcitabine for first-line treatment of Asian patients with advanced non-small-cell lung cancer harbouring EGFR mutations (LUX-Lung 6): an open-label, randomised phase 3 trial.
Wu YL; Zhou C; Hu CP; Feng J; Lu S; Huang Y; Li W; Hou M; Shi JH; Lee KY; Xu CR; Massey D; Kim M; Shi Y; Geater SL
Lancet Oncol; 2014 Feb; 15(2):213-22. PubMed ID: 24439929
[TBL] [Abstract][Full Text] [Related]
20. From Diagnostic-Therapeutic Pathways to Real-World Data: A Multicenter Prospective Study on Upfront Treatment for
Pasello G; Vicario G; Zustovich F; Oniga F; Gori S; Rosetti F; Bonetti A; Favaretto A; Toso S; Redelotti R; Santo A; Bernardi D; Giovanis P; Oliani C; Calvetti L; Gatti C; Palazzolo G; Baretta Z; Bortolami A; Bonanno L; Basso M; Menis J; Corte DD; Frega S; Guarneri V; Conte P;
Oncologist; 2019 Jun; 24(6):e318-e326. PubMed ID: 30846513
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
